Teachers Retirement System of The State of Kentucky lessened its position in Kenvue Inc. (NYSE:KVUE – Free Report) by 4.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 140,787 shares of the company’s stock after selling 7,240 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Kenvue were worth $3,021,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Kenvue by 12.0% in the 1st quarter. Vanguard Group Inc. now owns 166,789,085 shares of the company’s stock valued at $3,579,294,000 after acquiring an additional 17,908,497 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Kenvue by 23.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 134,565,333 shares of the company’s stock valued at $2,887,773,000 after purchasing an additional 25,238,112 shares during the last quarter. Wellington Management Group LLP lifted its position in Kenvue by 6.7% during the fourth quarter. Wellington Management Group LLP now owns 76,501,956 shares of the company’s stock worth $1,647,087,000 after buying an additional 4,815,126 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Kenvue by 11.1% during the first quarter. JPMorgan Chase & Co. now owns 68,319,998 shares of the company’s stock worth $1,466,147,000 after buying an additional 6,825,611 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in Kenvue by 9.1% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 66,665,454 shares of the company’s stock worth $1,435,307,000 after buying an additional 5,574,265 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.
Kenvue Stock Performance
Shares of KVUE stock traded up $0.19 during trading hours on Friday, hitting $18.82. The stock had a trading volume of 17,688,715 shares, compared to its average volume of 16,514,614. The stock’s 50 day moving average is $18.49 and its 200 day moving average is $19.44. The firm has a market capitalization of $36.04 billion, a PE ratio of 24.13, a PEG ratio of 2.07 and a beta of 1.38. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.43. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.99 and a quick ratio of 0.68.
Kenvue Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 28th. Shareholders of record on Wednesday, August 14th will be given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 4.36%. This is a boost from Kenvue’s previous quarterly dividend of $0.20. The ex-dividend date is Wednesday, August 14th. Kenvue’s dividend payout ratio (DPR) is presently 102.56%.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on KVUE shares. HSBC lifted their price target on Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a report on Wednesday, May 8th. Sanford C. Bernstein began coverage on shares of Kenvue in a research note on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price target for the company. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Kenvue from $24.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, July 25th. JPMorgan Chase & Co. lowered their price objective on Kenvue from $23.00 to $22.00 and set an “overweight” rating for the company in a research report on Monday, July 22nd. Finally, Citigroup reduced their target price on Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Kenvue has a consensus rating of “Hold” and a consensus price target of $22.45.
View Our Latest Analysis on KVUE
Kenvue Company Profile
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
- Five stocks we like better than Kenvue
- Learn Technical Analysis Skills to Master the Stock Market
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.